TeneoThree

TeneoThree is a biotechnology company affiliated with Teneobio that was used in connection with development of TNB-585, a PSMA x CD3 bispecific T-cell engager for metastatic castration-resistant prostate cancer. Publicly available evidence indicates that TeneoThree operated as an affiliate legal entity rather than as a broad standalone operating biotech with a separately disclosed pipeline. Its known clinical asset, TNB-585, entered Phase 1 in 2021 and was later integrated into Amgen following Amgen's acquisition of Teneobio in October 2021. The program has subsequently been referred to by Amgen as AMG 340. Overall, TeneoThree appears to have been a health-related corporate vehicle tied to Teneobio's antibody platform and prostate cancer bispecific program.